Matosin, Natalie http://orcid.org/0000-0003-3208-1311
Arloth, Janine
Czamara, Darina
Edmond, Katrina Z.
Maitra, Malosree
Fröhlich, Anna S.
Martinelli, Silvia
Kaul, Dominic
Bartlett, Rachael
Curry, Amber R.
Gassen, Nils C.
Hafner, Kathrin
Müller, Nikola S.
Worf, Karolina
Rehawi, Ghalia
Nagy, Corina
Halldorsdottir, Thorhildur
Cruceanu, Cristiana
Gagliardi, Miriam
Gerstner, Nathalie
Ködel, Maik
Murek, Vanessa
Ziller, Michael J.
Scarr, Elizabeth
Tao, Ran
Jaffe, Andrew E.
Arzberger, Thomas
Falkai, Peter
Kleinmann, Joel E.
Weinberger, Daniel R.
Mechawar, Naguib
Schmitt, Andrea
Dean, Brian
Turecki, Gustavo
Hyde, Thomas M.
Binder, Elisabeth B.
Funding for this research was provided by:
Rebecca L. Cooper Medical Research Foundation (PG2020645, Al, Val Rosenstrauss Fellowship)
National Health and Medical Research Council (APP1105445)
Alexander von Humboldt-Stiftung (Research Fellowship)
International Brain Research Organization (Research Fellowship)
National Alliance for Research on Schizophrenia and Depression (26486, 28063, 25348)
Canadian Institutes of Health Research
Max Planck Institute of Psychiatry
Article History
Received: 19 December 2022
Revised: 18 January 2023
Accepted: 19 January 2023
First Online: 2 February 2023
Declarations
:
: Dr Binder is a co-inventor of the following patent applications: FKBP5: a novel target for antidepressant therapy. European Patent # EP1687443 B1: Polymorphisms in ABCB1 associated with a lack of clinical response to medicaments. United States Patent # 8030033; Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (TESI). European application number: 08016477.5, international application number: PCT/EP2009/061575. Dr Falkai has been an honorary speaker for AstraZeneca, Bristol Myers Squibb, Eli Lilly, Essex, GE Healthcare, GlaxoSmithKline, Janssen Cilag, Lundbeck, Otsuka, Pfizer, Servier and Takeda. During the past 5 years, but not presently, Dr Falkai has been a member of the advisory boards of Janssen-Cilag, AstraZeneca, Eli Lilly and Lundbeck. Dr Schmitt has been an honorary speaker for TAD Pharma and Roche and has been a member of advisory boards for Roche. The remaining authors declare no competing interests or conflicts of interest.